HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Carson expects to net $40 mil. from South African subsidiary stock sale.

This article was originally published in The Rose Sheet

Executive Summary

CARSON EXPECTS TO NET ROUGHLY $40 MIL. FROM SOUTH AFRICA public offering of the firm's subsidiary, Carson Holdings, on the Johannesburg stock exchange, Carson, Inc. Chairman and CEO Roy Keith told securities analysts during a conference call April 23. The majority of the proceeds from the offering will be used to build Carson's U.S. business, which has been struggling over the past few quarters. Remaining proceeds, expected to be generated from the offering, will be applied to the South African subsidiary to meet "growth needs for the next several years," Keith explained. Standard Bank in South Africa is expected to handle the transaction. Carson will begin a South African road show in early May to gauge interest in the proposed public offering, Keith noted.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel